Skip to main content

Aclaris Therapeutics, Inc.

For the period ended Jun 5, 2025. Filed Apr 24, 2025.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Jun 5, 2025 · Filed Apr 24, 2025

ACRS$3.90+8.0%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Summary Compensation Table

The following table presents the compensation awarded to or earned by each of our NEOs for the years ended December 31, 2024 and 2023.

​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​Non-Equity​​​​
​​​​​​​​Stock​Option​Incentive Plan​All Other​​
​​​​Salary​​​Awards​Awards​Compensation​Compensation​Total
Name and Principal PositionYear($)Bonus($)(1)($)(1)($)(2)($)($)
Neal Walker(3)​2024​477,431​—​170,400​421,586​372,396​3,322(4)​1,445,135
Interim Chief Executive Officer​​​​​​​​
Douglas Manion(5)​2024​27,083​—​—​—​—​828,998(6)​856,081
Former Chief Executive Officer and President2023600,000—1,832,7604,513,721198,00013,200(7)​7,157,681
Hugh Davis(8)202462,500—423,7201,076,67430,6251,666(7)​1,595,185
President and Chief Operating Officer
Kevin Balthaser2024444,000—247,800179,003217,56013,800(7)​1,102,163
Chief Financial Officer2023444,000—509,1001,253,812124,32013,200(7)​2,344,432
(1)The amounts reflect the full grant date fair value for RSU and stock option awards granted during the indicated year. The grant date fair value was computed in accordance with ASC Topic 718, Compensation—Stock Compensation. The assumptions we used in valuing stock options and restricted stock unit awards are described in Note 7 to our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024.
(2)The amounts reflect the portion of each officer’s target annual bonus paid based on the achievement of our corporate and individual goals, as applicable, which for 2024 are discussed further below under “Narrative to Summary Compensation Table—Annual Bonus (Non-Equity Incentive Plan Compensation).”
(3)Dr. Walker’s employment with us commenced in January 2024.
(4)The amount consists of fees paid under our director compensation policy for his service as our Chair of the Board prior to Dr. Walker being appointed as our Interim Chief Executive Officer in January 2024.
(5)Dr. Manion’s employment with us ended in January 2024.
(6)The amount consists of (i) $3,115 in company matching contributions to Dr. Manion’s 401(k) plan account, (ii) the following accrued payments in connection with his separation agreement entered into in February 2024: (a) $600,000, representing 12 months’ base salary and (b) $198,000, representing 100% of his 2023 target bonus, and (iii) $27,883, representing accrued but unused vacation time paid out upon termination of his employment.
(7)The amount consists of company matching contributions to the executive’s 401(k) plan account.
(8)Dr. Davis’s employment with us commenced in November 2024.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.